Aarti Industries Ltd · NSE:AARTIIND
Aarti Industries — Shareholder Meeting (September 2022)
28 slides from Aarti Industries's shareholder meeting presentation, Sep 26, 2022
Slide 1: Aarti Industries Limited – Investor Presentation filing letter
AARTI INDUSTRIES LIMITED September 26, 2022 To, To, Listing/Compliance Department Listing/Compliance Department National Stock Exchange of BSE LTD. Phiroze Jeejeebhoy Towers, India Limited Dalal Street, "Exchange Plaza", Plot No. C/1, Mumbai - 400 001. G Block Bandra-Kurla Complex, Bandra·(E), Mumba
Slide 2: Annual General Meeting 26 September 2022
Annual General Meeting 26 September 2022
Slide 3: Disclaimer
Disclaimer AARTI INDUSTRIES LIMITED may, from time to time, make written and oral forward looking statements, in addition to statements contained in the company's filings with BSE Limited [BSE] and National Stock Exchange of India Limited [NSE], and our reports to shareholders. The company does not
Slide 4: Agenda
Agenda 01 Company Overview 02 Financial Snapshot & Shareholder Info 03 Strengths 04 Growth Opportunity & Strategy 05 Demerger Proposal 06 Corporate Social Responsibility
Slide 5: About Aarti Industries (AIL)
About Aarti Industries (AIL) Overview Key Metrics A leading Speciality Chemicals company in Benzene & Toulene based derivatives with integrated operations and high level of cost optimization 200+ 400+ 700+ Products Global Customers Domestic Pharma operations spanning APIs, intermediates and Xant
Slide 6: Agenda
Agenda 01 Company Overview 02 Financial Snapshot & Shareholder Info 03 Strengths 04 Growth Opportunity & Strategy 05 Demerger Proposal 06 Corporate Social Responsibility
Slide 7: FY22 – Financial Highlights & Key Updates
FY22 – Financial Highlights & Key Updates FY22 vs FY21 INR 7919 58% INR 1930 96% INR 1527 130% INR 1307 144% crore crore crore crore Revenues Revenues EBITDA Profit Before Tax Profit After Tax INR 1200 crore Fund raised through • Robust revenue momentum supported by better realisations trends owing
Slide 8: FY22 Highlights (Consolidated)
FY22 Highlights (Consolidated) Revenues EBITDA 58% 7,919 96% 7,288 5,023 1320 982 1930 FY21 FY22 FY22 FY21 FY22 FY22 Without With Without With termination termination termination termination income income income income Profit Before Tax Profit After Tax 1,307 1527 130% 144% 917 665 535 FY21
Slide 9: FY2021-22 Highlights (Consolidated)
FY2021-22 Highlights (Consolidated) Chemical Segment • For FY22, segment revenue includes Pharma Segment long-term contract termination fees of Revenue Rs. 631 crore and EBIT includes the Revenue impact of the same of Rs. 610 crore 1,300 63% 37% 6,619 • Successfully passed on impact of 5,988 952
Slide 10: 10 Years Highlights
10 Years Highlights Revenues PAT 1307 7919 3163 328 1667 104 FY12 FY17 FY22 FY12 FY17 FY22 Gross Block Market Capitalization 6272 31500 2655 6287 855 478 FY12 FY17 FY22 FY12 FY17 Current Amount in INR (Cr)
Slide 11: Financials - Consolidated
Financials - Consolidated Robust Revenue Growth Strong EBITDA Growth Strong PAT Growth INR (Cr) INR (Cr) INR (Cr) 1,307 7,919 1,930 4,705 4,621 5,023 3,806 965 977 982 699 492 536 535 333 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Significant Capex Undertaken Strong R
Slide 12: Shareholders Info
Shareholders Info Shareholders Base Shareholding Pattern (%) 337948 265330 Public, 29 Promoter, 44 123044 Foreign 42051 23259 26113 Institutions, 12 Sep-17 Sep-18 Sep-19 Sep-20 Sep-21 Sep-22 Domestic Institutions, 15 Market Cap (Rs. Cr) 40000 34692 31500 30000 22939 18581 20000 13633 9323 10000 6287
Slide 13: Q1 FY23 – Financial Highlights & Key Updates
Q1 FY23 – Financial Highlights & Key Updates INR 2173 45% INR 369 18% INR 233 13% INR 189 15% Q1 FY23 vs crore crore crore crore Q1 FY22 Revenues Revenues EBITDA Profit Before Tax Profit After Tax • Significant increase in revenues was on account of pass-on for the elevated 54 : 46 Inputs prices, Ut
Slide 14: Performance Overview – Q1 FY23
Performance Overview – Q1 FY23 Revenues of Rs. 2,173 crore; EBITDA of Rs. 369 crore; PAT of Rs. 189 crore; YoY increase of 45% YoY growth of 18% YoY up by 15% • Revenue trajectory was steered by higher volume off take for key products, favourable realization gains and passon of higher costs. This wa
Slide 15: Agenda
Agenda 01 Company Overview 02 Financial Snapshot & Shareholder Info 03 Strengths 04 Growth Opportunity & Strategy 05 Demerger Proposal 06 Corporate Social Responsibility
Slide 16: Key Strengths
Key Strengths Global Player in Benzene based Derivatives with Integrated Operations • Strong/Leadership position in key products and processes • Integrated operations across product chain of Benzene and Toluene • Ability to effectively use co-products and generate value-added products Well Diversifi
Slide 17: ESG for AIL
ESG for AIL Our Strategy : Growth with Sustainability for a Sustainable Growth ESG factors are core part of our decision making process. We monitor our performance on below mentioned ESG parameters: Environment • GHG & atmospheric • Materials Emissions • Waste • Water • Energy Environment • Effluent
Slide 18: Recognition on ESG
Recognition on ESG AIL awarded RC in Feb AIL awarded Gold Award by ESG Rating by 2022 EcoVadis CRISIL 01 Responsible Care’ is the global EcoVadis is the world’s most trusted CRISIL independently evaluated top chemical industry’s commitment to business Sustainability Ratings, used 225 companies acros
Slide 19: Well placed to benefit from sector tailwinds – Global
Well placed to benefit from sector tailwinds – Global Global Speciality chemicals market size and region-wise share (USD Global Speciality chemicals market size and region-wise share Bn) 2020 Others 15% China 830-850 26% 740-760 Other Asia 595 11% 740-760 India US$ Bn 4% Japan North America 8% 21% 2
Slide 20: India is emerging as an alternative to China due to various factors
India is emerging as an alternative to China due to various factors India has grown a critical mass and several Indian Companies are eager to Invest creating global sized plants to cater to growing domestic and global demand Global multinationals need alternate sourcing destinations from China to de
Slide 21: Agenda
Agenda 01 Company Overview 02 Financial Snapshot & Shareholder Info 03 Strengths 04 Growth Opportunity & Strategy 05 Demerger Proposal 06 Corporate Social Responsibility
Slide 22: Key Highlights – Future Growth Projects FY23-24
Future Growth Projects: FY23-24 (Driven by R&D & Innovation) Introducing Chloro Toulenes Value Chain: (Range of Key Highlights products) ● Adding new chemistries and Value added products Newer range of o 40+ products for Chemicals Setting up Value Added 50+ products for Pharma Universal o products &
Slide 23: Growth Estimates
Growth Estimates Turnover: 2.5x-3.5x EBIDTA: 3x - 4x PAT: 3x - 4x Turnover: 1.7x -2.0x FY27 Growth EBIDTA: 1.7x - 2.0x (over FY21) PAT: 1.7x – 2.0x FY24 Growth Turnover Rs. 7919 Cr. (over FY21) EBIDTA: Rs. 1929 Cr. PAT: Rs. 1307 Cr. Turnover: Rs. 5,000 FY22 Cr. Snapshot EBIDTA: Rs. 980 Cr. PAT: Rs 5
Slide 24: Agenda
Agenda 01 Company Overview 02 Financial Snapshot & Shareholder Info 03 Strengths 04 Growth Opportunity & Strategy 05 Demerger Proposal 06 Corporate Social Responsibility
Slide 25: Pharmaceuticals – Exposure to multiple segments & products
Pharmaceuticals – Exposure to multiple segments & products with strong growth opportunities, demerger proposal Pharma - Significant Top Line and Margin Growth… CAGR FY18-22: 24% CAGR FY18-22: 29% 113 137 211 220 556 726 756 952 1300 79 FY18 FY19 FY20 FY21 FY22 FY18 FY19 FY20 FY21 FY22 Revenue (Rs Cr
Slide 26: Agenda
Agenda 01 Company Overview 02 Financial Snapshot & Shareholder Info 03 Strengths 04 Growth Opportunity & Strategy 05 Demerger Proposal 06 Corporate Social Responsibility
Slide 27: Contributing for Social Development
Contributing for Social Development COVID-19 Efforts INR 12.62 crs 12,45,633 Amount Spent on CSR activities Lives impacted by our CSR activities Cluster & Rural Education & Skill Development Development Together for prosperity ‘Nearly 260 million people who are below the poverty line have to join ma
Slide 28: Thank You
THANK YOU Contact: +91 22 67976666 Email: info@aarti-industries.com
Aarti Industries — Shareholder Meeting (September 2022) on 6ix